Furthermore, we have shown that NF1 gene expression is associated with neuroblastoma patient outcomes, suggesting that MEK inhibitors would be most effective in patients with the worst outcomes and that NF1 expression represents a potentially useful biomarker for response to RAS/MAPK pathway inhibition. This evidence concerns the gene NF1 and neuroblastoma.